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ABSTRACT
The performances of the QuantiFERON-TB Gold
in Tubes (QFGT), T SPOT-TB (ELISPOT) and the
Mantoux test were compared for the diagnosis of
latent tuberculosis infection in Finland, a country
of low tuberculosis incidence. In Cohort A (16
students), freshly isolated peripheral blood mono-
nuclear cells (PBMCs), and in Cohort B (21 school
children), cryopreserved PBMCs, were used for
the ELISPOT assay. Cryopreservation of cells in
fetal calf serum, but not in serum-free medium,
produced false-positive results. Discrepancies
between the results of the assays were observed.
It was concluded that the accuracy of these
ex-vivo methods needs additional evaluation.
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Two new immunological assays, QuantiFERON-
TB Gold in Tubes (QFGT) (Cellestis Ltd, Carnegie,
Australia) and T SPOT-TB (ELISPOT) (Oxford
Immunotec, Oxford, UK), have become available
for the ex-vivo diagnosis of Mycobacterium tuber-
culosis infections. These assays detect secreted
interferon (IFN)-c or IFN-c-secreting cells, respect-
ively, induced by stimulation of whole blood
(QFGT) or isolated peripheral blood mononuclear
cells (PBMCs) (ELISPOT) by the M. tuberculosis
antigens absent in the bacille Calmette–Gue´rin
(BCG) vaccine strain [1–5]. Most previous studies
have suggested that these methods are superior to
the tuberculin skin test (TST), but most of these
studies were performed in populations with a
high tuberculosis (TB) burden and, in the absence
of a reference standard, may have overestimated
the prevalence of latent TB infection [6,7].
Furthermore, little attention has been paid to the
effects of pre-analytical factors, e.g., sample trans-
port and preservation of cells, on the outcome
of the ELISPOT test. The IFN-c-based methods
have not been evaluated previously in a country
with a low incidence of TB, such as Finland
(6.6 cases ⁄ 100 000 inhabitants), where almost
98% of the population is vaccinated with BCG.
The aims of the present study were: (i) to
compare the performance of the new IFN-c-based
methods and the TST; (ii) to evaluate the feasibility
of using the ELISPOT method with cells cryo-
preserved by a conventional method in fetal calf
serum (FCS) or by an alternative cryopreservation
method in a serum-free matrix protein mixture;
and (iii) to investigate the effect of prolongation
of cell cultivation for 5 days on the ELISPOT
results. The study was approved by the Ethical
Committees of the respective Hospital Districts.
Cohort A comprised 16 BCG-vaccinated medical
students from Finland who participated in an
autopsy of a cadaver with disseminated TB. During
the autopsy examination, every individual wore
surgical, but not special respirator (FFP3), masks.
The maximal exposure time was 3 h. QFGT tests
were performed according to the manufacturer’s
instructions after 6 weeks, and TSTs (PPD; Statens
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Serum Institut, Copenhagen, Denmark; 2 TU ⁄ 0.1
mL) were performed and evaluated 3 days later.
Chest X-rays were taken 6 months post-autopsy.
After 11 months, the post-autopsy QFGT tests
were repeated, but the ELISPOT test was perfor-
med using transported EDTA–blood (maximal
transportation time of 6 h). Upon arrival the blood
tubes were cold, but no haemolysis was observed.
The effect on the ELISPOT results of prolonging
incubation for 5 days was also evaluated.
Fig. 1 represents the combined data from the
study. One student in Cohort A was non-reactive
in the ELISPOT assay, but repeatedly positive
according to the QFGT assay, with an initial IFN-c
value of 23.4 IU ⁄mL (cut-off 0.35 IU ⁄mL); this
decreased after a further 9 months to 0.84 IU ⁄mL
without any intervention. The reasons for this
decline in the QFGT OR value and the discrep-
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Fig. 1. Results obtained for 16 students in Finland follow-
ing brief exposure to latent tuberculosis infection. (a) T
SPOT-TB (ELISPOT) assay results, obtained following the
instructions of the manufacturer. (b) Mantoux reaction. (c)
Interferon (IFN)-c levels obtained using the QuantiFERON-
TB Gold in Tubes (QFGT) assay. (d) The effect of prolon-
gation (5 days) of cell incubation on the ELISPOT results.
The solid lines (a, c, d) show the cut-off values defined by
the manufacturers, i.e., six spots ⁄ 250 000 peripheral blood
mononuclear cells (PBMCs) for the ELISPOT assay, and
0.35 IU ⁄mL for the QFGT assay. The broken lines (a, d)
show the cut-off value for the ELISPOT assay, as defined by
the user for cryopreserved samples. Only the highest
response to either the ESAT-6 or CFP-10 peptide mixture
is shown for the ELISPOT (a, d). * denotes a weak primary
response to pytohaemagglutinin, which was adequate on
repeat. Note that the reactivity in the QFGT method
changed with time for student no. 6. Prolongation of cell
cultivation in the ELISPOT assay produced high non-
specific reactivity with almost every sample.
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Fig. 2. Results obtained with the T Spot-TB (ELISPOT)
assay for 21 schoolchildren in Finland after exposure to
latent tuberculosis infection. (a) Initial ELISPOT results
obtained when the test was performed with cells cryopre-
served in fetal calf serum (FCS). (b) Results of repeat
ELISPOT tests obtained with the original ampoules of
cryopreserved cells in FCS (s), samples 3, 7, 16 and 20.
Note the poor between-run reproducibility with sample 16.
The number of cells from sample 5 was insufficient to allow
retesting from the same ampoule. A new sample from
this individual was retested from cells cryopreserved
in CTL medium (r) and from freshly isolated cells (d);
the retest from the new sample for cells cryopreserved
in FCS produced a high non-specific background of
172 cells ⁄ 250 000 peripheral blood mononuclear cells
(PBMCs) (data not shown). The solid line shows the
cut-off value defined by the manufacturer (i.e., six
spots ⁄ 250 000 PBMCs). The broken line indicates the cut--
off value defined by the user for cryopreserved samples
(i.e., 13 spots ⁄ 250 000 PBMCs). Only the highest response
to either the ESAT-6 or CFP-10 peptide mixture is shown.
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ancy between the methods are not understood,
but it is possible that this student was infected
and spontaneous clearance of infection occurred.
Other plausible explanations are that the QFGT
assay has a low reproducibility and the observed
reaction was not specific, or that the lymphocytes
of this sample deteriorated slightly during
transportation, resulting in non-reactivity in the
ELISPOT assay (although the reactivity to phyto-
haemagglutinin, an indicator of the cell viability,
was acceptable). Three (18%) of the 16 students
had a TST reaction of >15 mm, but remained
symptomless, suggesting a low specificity of the
TST with the population in Finland.
Cohort B comprised 21 school children exposed
for several months to a fellow student with culture-
positive pulmonary TB. In total, 177 of 263 iden-
tified contacts were examined by chest X-ray at
least twice within 6 months, with normal results.
After a further 9 months, 21 students volunteered
to participate in the present study to estimate
the utility of the ELISPOT method. Because of
logistical problems with sample transport (600 km),
the blood was collected in CTP tubes (Becton
Dickinson, Franklin Lakes, NJ, USA). The PBMCs
were then isolated and immediately cryopreserved
in dimethylsulphoxide 10% v ⁄v:FCS 90% v ⁄v as
described previously [8]. The ampoules containing
cells were then stored at )70C until tested.
One student in Cohort B was initially positive
in the ELISPOT assay, but donated blood tested
3 weeks later was non-reactive according to the
QFGT assay. After a further 14 months, a new
blood sample was taken and the ELISPOT test
was repeated using fresh PBMCs and cells cryo-
preserved in FCS and in CTL medium (CTL
Europe, Aalen, Germany). The results (Fig. 2)
demonstrate clearly that the ELISPOT performed
better with freshly isolated PBMCs, but was less
specific when the cells were cryopreserved in CTL
medium. Conventional cryopreservation in FCS,
although often done [9], may cause a significant
deterioration in the specificity of the assay (e.g.,
sample no. 5, Fig. 2). Indeed, the manufacturer of
the ELISPOT assay recommends that only freshly
isolated cells should be used. However, this is
impractical, especially in a sparsely populated
area with a varying climate. The pre-analytical
freezing step is most useful and should not be
discouraged if performed correctly.
In conclusion, the results of this feasibility
study indicate: (i) that the new IFN-c-based
methods could eventually replace TSTs, especially
in countries with high BCG vaccination coverage;
(ii) that cryopreservation of isolated PBMCs in
FCS may result in non-specific background sig-
nals in the ELISPOT assay, thereby impairing its
specificity, although this problem may be avoided
by the use of serum-free cryopreservation med-
ium; and (iii) that prolongation of the incubation
from 1 to 5 days in the ELISPOT assay seems to
lead to increased non-specific reactivities rather
than detection of the memory T-cell pool [3].
Additional experience is required to determine
whether these methods should be considered
quantitative and suitable for long-term monitor-
ing. The cut-off levels to ensure the best clinical
specificity also need further evaluation.
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